EVAX

Evaxion A/S is a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies. The company uses artificial intelligence and machine learning algorithms to discover and develop novel cancer immunotherapies and vaccines for infectious diseases. Evaxion's proprietary technology platform analyzes large datasets to identify patient-specific neoantigens and design personalized cancer vaccines. The company's pipeline includes therapeutic cancer vaccine candidates and vaccine programs targeting bacterial and viral infections. Headquartered in Denmark, Evaxion represents the intersection of artificial intelligence and immunotherapy development.